Pomerantz Law Firm Alerts Investors on Mereo BioPharma Class Action Lawsuit and Important Deadlines Pomerantz LLP announces a class action lawsuit against Mereo BioPharma Group plc for investors who incurred losses. Key deadlines are approaching.

Pomerantz Law Firm Alerts Investors on Mereo BioPharma Class Action Lawsuit and Important Deadlines #USA #New_York #Pomerantz_LLP #Mereo_BioPharma #MREO

Class Action Lawsuit Against Mereo BioPharma Group plc for Securities Violations Mereo BioPharma Group has been hit with a class action lawsuit for allegedly misleading investors about the failure of its clinical trials. Find out how this may affect shareholders.

Class Action Lawsuit Against Mereo BioPharma Group plc for Securities Violations #United_States #New_York #DJS_Law_Group #Mereo_BioPharma #MREO

Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Mereo (NASDAQ: MREO) reported full‑year 2025 results and clinical updates on March 19, 2026. Cash was $41.0 million as of December 31, 2025, with a stated runway into mid‑2027.Phase 3 Orbit and Cosmic studies of setrusumab missed primary fracture endpoints but showed statistically significant BMD gains, reductions in vertebral fractures and improved pediatric PROs. Alvelestat Phase 3 planning completed site feasibility (≈220 patients). Vantictumab was outlicensed with a partner planning a Phase 2 in H2 2026.

#MREO Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights

www.stocktitan.net/news/MREO/mereo-bio-phar...

Mereo BioPharma Faces Class Action Lawsuit Over Securities Violations Mereo BioPharma Group plc is under scrutiny with a class action lawsuit for alleged securities law violations. Find out more about your rights.

Mereo BioPharma Faces Class Action Lawsuit Over Securities Violations #United_States #DJS_Law_Group #Eastchester #Mereo_BioPharma #MREO

🤔 A split between caution and speculation — some seeing the stock as high-risk and others watching for a potential rebound, with high trading volume and volatility fuelling debate. #MREO

source: Quiver Quantitative

#MREO super oversold and deserves attention on the rebound

Today’s most cited tickers with positive sentiment (last 24h):

#CETX: 24
#TSLA: 21
#ASTS: 17
#SPY: 17
#NVDA: 13
#SLS: 11
#AMZN: 10
#OTLK: 8
#NKE: 8
#BTC: 7
#NXXT: 7
#SLV: 7
#EKSO: 7
#MREO: 6
#AAPL: 6
#MU: 6
#GOOG: 5
#GOOGL: 5

📢 Stocks Trending NOW: #CETX #RARE #BIDU #EKSO #PFSA #MREO #DRMA #BNAI #CROX #NEM

Most Searched, Monday December 29, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Dec 29th - #NUAI #GVH #WOK #EXK #RZLV #RARE #SLS #RXRX #RR #PALI #QUBT #PLUG #DBRG #MREO #UUUU #STKE #ONDS #NAK #MARA #ELME - More: crystalequityresearch.com/most-searche... - #smallcap

Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of improvements in bone mineral density with strong statistical significance LONDON, Dec. 29, 2025 (GLOBE

#MREO Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta

www.stocktitan.net/news/MREO/mereo-bio-phar...

Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights  Mereo (NASDAQ: MREO) reported Q3 2025 results and corporate highlights on Nov 10, 2025. Key near-term catalysts include Phase 3 Orbit and Cosmic setrusumab readouts expected around the end of 2025 (Orbit final analysis threshold p<0.039; Cosmic p<0.05).Financials: cash $48.7M as of Sep 30, 2025, expected to fund operations into 2027; Q3 R&D expense rose to $4.3M (vs $3.2M prior year); G&A was $6.0M; net loss was $7.0M in Q3 2025.Corporate items: ongoing alvelestat partnering discussions, retained European commercial rights for vantictumab, and continued pre-commercial work in Europe for setrusumab.

#MREO Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights 

www.stocktitan.net/news/MREO/mereo-bio-phar...

First Potential Treatment for 1-in-20,000 Bone Disease: āshibio Advances Novel Antibody Therapy āshibio gains global rights (ex-Europe) to develop vantictumab for autosomal dominant osteopetrosis type 2. Drug shows promising safety data from previous trials. Disease affects 1 in 20,000 births.

#MREO āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

www.stocktitan.net/news/MREO/ashibio-expand...

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights Mereo BioPharma (NASDAQ: MREO) has reported its Q2 2025 financial results and provided corporate updates. The company maintains a strong financial position with $56.1 million in cash as of June 30, 2025, expected to fund operations into 2027. Key highlights include the progression of two Phase 3 studies for setrusumab in osteogenesis imperfecta, with final analyses expected around year-end 2025.Financial results show R&D expenses increased to $5.4 million in Q2 2025 from $4.9 million in Q2 2024, while G&A expenses decreased to $5.5 million from $7.9 million. The company reported a net loss of $14.6 million for Q2 2025, compared to $12.3 million in Q2 2024. The Orbit study's Data Monitoring Committee confirmed setrusumab's acceptable safety profile, allowing the study to proceed to final analysis.

#MREO Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

www.stocktitan.net/news/MREO/mereo-bio-phar...

Pomerantz Law Firm Launches Investigation on Mereo BioPharma Group Investors' Claims Pomerantz LLP is investigating significant claims against Mereo BioPharma Group plc, focusing on potential securities fraud. Investors encouraged to reach out.

Pomerantz Law Firm Launches Investigation on Mereo BioPharma Group Investors' Claims #USA #New_York #Pomerantz_LLP #Mereo_BioPharma #MREO

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu Jul 10th - #RXRX #MREO #RUN #KLG #CIFR #AMPX #WULF #PROK #WOLF #IREN #BTCM #WRD #HIVE #HTZ #SQNS #MGNX #LEU #ISVLF #IQ #AVXL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

JUST IN: ( NASDAQ: #MREO ) Ultragenyx and Mereo Advance Bone Disease Therapy to Final Phase 3 Analysis

Ultragenyx and Mereo Advance Bone Disease Therapy to Final Phase 3 Analysis Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma (MREO) announced today that their joint Phase 3 clinical trial for UX143 (setrusumab), a potential treatmen

#RARE #MREO
#ultragenyx and #MereoBioPharma are making strides in rare disease treatment! Their bone disorder therapy is advancing to the final Phase 3 analysis, bringing new hope to patients worldwide.
prismmarketview.com/ultragenyx-a...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#MREO, #SPWH, #MGA, #ARCC, #CRON

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MREO 3.2x
2. #LULU 2.5x
3. #SPWH 2.1x
4. #DOCU 2.1x
5. #MGA 2.0x

#OptionFlow #OptionsTrading #Trading

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights Mereo BioPharma (NASDAQ: MREO) reported Q1 2025 financial results and corporate updates. The company's Phase 3 Orbit study of setrusumab for osteogenesis imperfecta is progressing towards a second interim analysis in mid-2025 or final analysis in Q4 2025. The company reported cash position of $62.5 million as of March 31, 2025, expected to fund operations into 2027. Q1 2025 financial highlights include R&D expenses of $3.9 million (down from $4.0 million in Q1 2024) and increased G&A expenses of $7.3 million (up from $5.9 million). The company posted a net loss of $12.9 million compared to $9.0 million in Q1 2024. Mereo continues advancing alvelestat, which received European Commission Orphan Designation for AATD-LD treatment, and is now Phase 3 ready.

#MREO Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

www.stocktitan.net/news/MREO/mereo-bio-phar...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#FOA, #BLDE, #MREO, #MGY, #WEX

#OptionFlow #OptionsTrading #Trading

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights Mereo BioPharma (NASDAQ: MREO) reported its full year 2024 financial results and corporate updates. The company's Phase 3 Orbit study of setrusumab in osteogenesis imperfecta is advancing toward a second interim analysis expected mid-2025. Alvelestat received European Commission Orphan Designation for Alpha-1 Antitrypsin Deficiency-associated Lung Disease treatment.Financial highlights include cash position of $69.8 million as of December 31, 2024, expected to fund operations into 2027. R&D expenses increased to $20.9 million from $17.4 million in 2023, while general and administrative expenses rose to $26.4 million from $18.4 million. The company reported a net loss of $43.3 million for 2024, compared to $29.5 million in 2023.Two global studies are progressing: the Phase 3 Orbit study and Cosmic study, evaluating setrusumab in OI patients. Pre-commercial activities are ongoing in Europe, with scientific advice obtained from GBA in Germany and NICE in the U.K.

#MREO Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

www.stocktitan.net/news/MREO/mereo-bio-phar...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#IMUX, #MREO, #PSN, #SMG, #ASPN

#OptionFlow #OptionsTrading #Trading

Mereo BioPharma's Setrusumab Advances Phase 3 Trial as Alvelestat Gains Key EU Support Mereo's dual program progress: Setrusumab Phase 3 interim analysis set for mid-2025, while Alvelestat receives positive EMA orphan drug opinion. Cash runway extends to 2027.

#MREO Mereo BioPharma Provides Update on Lead Clinical Programs

www.stocktitan.net/news/MREO/mereo-bio-phar...

#MREO Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

www.stocktitan.net/news/MREO/mereo-bio-phar...